Novartis AG Common Stock (NVS)

The pharmaceutical sector stands at the precipice of a profound transformation, driven by the relentless march of artificial intelligence (AI) and other advanced technologies. As highlighted by industry observers like PharmTech.com, rapid workforce upskilling is no longer a luxury but a critical necessity for companies aiming to thrive in this new era. The immediate significance [...]

San Francisco, CA – October 31, 2025 – Artificial intelligence (AI) is ushering in a transformative era for the pharmaceutical industry, particularly in the often-overlooked yet critical domain of excipient development. These "inactive" ingredients, which constitute the bulk of most drug formulations, are now at the forefront of an AI-driven innovation wave. By leveraging advanced [...]

Artificial intelligence (AI) is ushering in a transformative era for pharmaceutical research and development (R&D), fundamentally reshaping how new medicines are discovered, developed, and brought to market. Driven by advanced data integration and sophisticated analytics, AI is dramatically accelerating timelines, reducing costs, and significantly improving success rates across the entire drug development pipeline. This paradigm [...]

The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late 2025, an established force, fundamentally reshaping drug development and operational workflows. This shift is not merely incremental but a comprehensive revolution, accelerating Research & [...]

Novartis is set to boost its developmental pipeline with this acquisition.

International dividend stocks are finally having their moment after years of underperformance, and this single Vanguard fund captures the opportunity with rock-bottom fees.

Shares of United Therapeutics slipped slightly Wednesday on light sales of its bread-and-butter drug, Tyvaso.

Generic competition had a 7 percentage-point negative impact on the company's biggest drug.

Novartis Q3 sales rose 8% to $13.91 billion, missing estimates, as Kisqali and Kesimpta drove growth while U.S. generics weighed on results.

U.S. companies have struck more than $80 billion worth of deals in the past 24 hours, in the latest sign that mergers and acquisitions (M&A) are picking up after the tariff-induced cool-off earlier this year.

Novartis revealed plans of acquiring Avidity Biosciences Inc. in a $12 billion all-cash transaction. The announcement sent RNA shares soaring roughly 44% on Monday.

Biotechs like it are clearly valuable to strategic acquirers.

If all goes well, the company will be part of a much larger enterprise starting next year.

Investor optimism drives the S&P 500 to new records while Qualcomm steals the spotlight with an 11% surge after unveiling new AI chips.

Avidity Biosciences (RNA) to be acquired by Novartis in a $12 billion cash deal. H.C. Wainwright downgrades to Neutral.

Qualcomm shares were up more than 11% in Monday’s midday session after the company unveiled two AI accelerator chips.

Avidity Biosciences (NASDAQ: RNA) shares soar as Novartis (NYSE: NVS) agrees to acquire them for $12 billion in cash.

Novartis has agreed to buy Avidity Biosciences in a deal valued at $72 per share.

U.S. stock futures rose on Monday following Friday’s positive moves. Futures of major benchmark indices were higher.

San Diego, CA – October 24, 2025 – Inhibrx (NASDAQ: INBX) shares have surged dramatically, skyrocketing over 70% in pre-market and after-hours trading, following the announcement of overwhelmingly positive topline results from its registrational trial of ozekibart (INBRX-109) for advanced or metastatic, unresectable chondrosarcoma. This monumental achievement positions ozekibart as a potential